RxDoctor Payments Data

Francis Jenkins, MD

Pulmonary Disease · Athens, GANPI 1487640850

Payments from drug & device makers

$1,254in general payments, 2019–2025

Across 68 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$374
  • Insmed, Inc.$352
  • AstraZeneca$262
  • Octapharma USA, Inc.$94
  • Sunovion Pharmaceuticals Inc.$55
  • Shionogi Inc$44
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$1,06485%
  • Education$19015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,254 in reported general payments places this provider in the 25th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$124,860
Medicare patients
436
Services billed
1,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter293$228,678
Breo ElliptaFluticasone/Vilanterol223$103,911
Breztri AerosphereBudesonide/Glycopyr/Formoterol92$67,273
EliquisApixaban79$65,480
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr101$59,524
Dupixent SyringeDupilumab12$41,896
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium44$38,318
XareltoRivaroxaban40$34,602
SymbicortBudesonide/Formoterol Fumarate76$22,366
Spiriva RespimatTiotropium Bromide24$15,693
Albuterol Sulfate HfaAlbuterol Sulfate415$14,862
Advair HfaFluticasone Propion/Salmeterol38$12,305
Arnuity ElliptaFluticasone Furoate32$8,911
Combivent RespimatIpratropium/Albuterol Sulfate14$8,860
Roflumilast71$7,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$374$401,024649 claims
AstraZenecaBreztri Aerosphere, Symbicort$262$89,639168 claims
PfizerEliquis$15$65,48079 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →